Daniel De Carvalho, Co-Founder and Chief Scientific Officer of Adela, shared a post on LinkedIn about a paper by Jing Tan et al. published in Cancer Discovery:
“Ten years ago, we showed that reactivating transposable elements triggers an antiviral state in cancer cells, a process we named viral mimicry, unmasking tumors to the immune system (Roulois, Cell 2015).
This week, that idea reached patients: Viral-mimicry priming + anti-PD-1 in relapsed/refractory NK/T-cell lymphoma delivered 47.6% complete responses, 66.7% ORR, and ~50% 2-year OS, even after prior PD-1 failure (Huang, Cancer Discovery 2025).
Thrilled to see a basic mechanistic discovery translate to meaningful clinical benefit.”
Title: Priming with DNMT Inhibitors Potentiates PD-1 Immunotherapy by Triggering Viral Mimicry in Relapsed/Refractory NK/T-cell Lymphoma
Authors: Cheng Huang, Yan Gao, Jianfeng Chen, Jing Han Hong, Yue Jiang, Kelila Xin Ye Chai, Yingxi Li, Peili Wang, Yali Wang, Jiuping Gao, Xian Zeng, Rong Xiao, Haixia He, Peiyong Guan, Jason Yongsheng Chan, Jing Quan Lim, Anand D. Jeyasekharan, Huang Dachuan, Jin-Xin Bei, Bin Tean Teh, Soon Thye Lim, Qiang Yu, Choon Kiat Ong, Huiqiang Huang, Jing Tan.
You can read the full article in Cancer Discovery.
More posts featuring Daniel De Carvalho.